The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide (Q39719485)

14 September 2017

1 reference

title

The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide (English)

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

24 June 2022

0 references

1 reference

0 references

D. J. Girling

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A345572

24 June 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=345572

24 June 2022

publication date

1 March 1978

1 reference

full work available at URL

14 September 2017

https://api.elsevier.com/content/article/PII:0041387977900228?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

https://api.elsevier.com/content/article/PII:0041387977900228?httpAccept=text/plain

24 June 2022

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

24 June 2022

1 reference

14 September 2017

59

1 reference

14 September 2017

13-32

1 reference

14 September 2017

1

1 reference

Preventive therapy of tuberculous infection

14 September 2017

1

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

Serum enzyme changes in patients receiving antituberculosis therapy with rifampicin or p-aminosalicylic acid, plus isoniazid and streptomycin

2 April 2023

3

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

Co-operative controlled trial of a standard regimen of streptomycin, PAS and isoniazid and three alternative regimens of chemotherapy in Britain. A report from the British Medical Research Council

2 April 2023

5

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

The competing risks of tuberculosis and hepatitis for adult tuberculin reactors

2 April 2023

8

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa--third investigation: the effect of an initial streptomycin supplement

2 April 2023

13

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

A controlled comparison of four regimens of streptomycin plus pyrazinamide in the retreatment of pulmonary tuberculosis

2 April 2023

15

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis

2 April 2023

18

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

Pharmacokinetics of isoniazid metabolism in man

2 April 2023

21

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens

2 April 2023

22

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

Short course chemotherapy for pulmonary tuberculosis

2 April 2023

24

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

The modern management and therapy of pulmonary tuberculosis

2 April 2023

25

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

Adverse reactions to short-course regimens containing streptomycin, isoniazid, pyrazinamide and rifampicin in Hong Kong

2 April 2023

26

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

Effect of Rifampicin and Isoniazid on Liver Function

2 April 2023

29

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

Toxicity form rifampicin plus isoniazid and rifampicin plus ethambutol therapy

2 April 2023

30

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

The use of pyrazinamide plus isoniazid in the treatment of pulmonary tuberculosis

2 April 2023

32

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

2 April 2023

Isoniazid hepatitis

33

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

Pyrazinamide-isoniazid in tuberculosis

2 April 2023

34

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

An international co-operative investigation into thiacetazone (thioacetazone) side-effects.

2 April 2023

39

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites

2 April 2023

41

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis

2 April 2023

42

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

A comparative study of daily followed by twice or once weekly regimens of ethambutol and rifampicin in retreatment of patients with pulmonary tuberculosis. The results at 1 year. A cooperative tuberculosis chemotherapy study in Poland

2 April 2023

43

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

Isoniazid and Iproniazid: Activation of Metabolites to Toxic Intermediates in Man and Rat

2 April 2023

44

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

A constant-rate infusion apparatus

2 April 2023

46

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

Study of adverse reactions to a once-weekly regimen of streptomycin plus a slow-release preparation of isoniazid in high dosage for six months

2 April 2023

51

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

A controlled clinical trial of the role of thiacetazone-containing regimens in the treatment of pulmonary tuberculosis in Singapore. Singapore Tuberculosis Services-Brompton Hospital-British Medical Research Council Investigation

2 April 2023

53

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

A slow-release preparation of isoniazid: therapeutic efficacy and adverse side-effects

2 April 2023

55

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India

2 April 2023

57

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis: 1. An assessment of two vitamin B preparations and glutamic acid

2 April 2023

59

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis

2 April 2023

63

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

Controlled comparison of oral twice-weekly and oral daily isoniazid plus PAS in newly diagnosed pulmonary tuberculosis

2 April 2023

64

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

A CONTROLLED COMPARISON OF STREPTOMYCIN PLUS PYRAZINAMIDE AND STREPTOMYCIN PLUS PAS IN THE RETREATMENT OF PATIENTS EXCRETING ISONIAZID-RESISTANT ORGANISMS.

2 April 2023

66

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

A study of two twice-weekly and once-weekly continuation regimen of tuberculosis chemotherapy, including a comparison of two durations of treatment. 1. First report: the results at 18 months

2 April 2023

69

1 reference

https://api.crossref.org/works/10.1016/0041-3879(77)90022-8

2 April 2023

Identifiers

1 reference

14 September 2017

1 reference